SenzaGen Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
33
- Stock Symbol
-
SENZA
- Investments
-
2
- Share Price
-
$0.68
- (As of Thursday Closing)
SenzaGen General Information
Description
SenzaGen AB markets, sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.
Contact Information
- Medicon Village, Building 401
- Scheelevägen 2
- 223 81 Lund
- Sweden
SenzaGen Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.68 | $0.70 | $0.60 - $1.34 | $16.6M | 24.2M | 9.9K | -$0.09 |
SenzaGen Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 21,432 | 23,067 | 17,731 | 23,228 |
| Revenue | 4,292 | 4,117 | 1,796 | 863 |
| EBITDA | (2,259) | (1,544) | (3,162) | (2,524) |
| Net Income | (2,240) | (2,456) | (3,650) | (2,947) |
| Total Assets | 9,368 | 11,499 | 14,785 | 13,598 |
| Total Debt | 100 | 116 | 79 | 0 |
SenzaGen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SenzaGen Patents
SenzaGen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220026411-A1 | Analytical methods and arrays for use in the same | Pending | 03-Jan-2019 | 0000000000 | |
| AU-2020205151-A1 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method | Pending | 03-Jan-2019 | 00000000000 | |
| CA-3123717-A1 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method | Pending | 03-Jan-2019 | 00000000000 | |
| EP-3906323-A2 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method | Pending | 03-Jan-2019 | 00000000000 | |
| EP-3688145-B1 | Novel cell line and uses thereof | Active | 25-Sep-2017 | G01N33/5044 |
SenzaGen Executive Team (8)
SenzaGen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
SenzaGen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SenzaGen Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Toxhub | 11-Nov-2022 | 0000000000 | 00000 | Consulting Services (B2B) | 00000 000 |
| VitroScreen | 02-Nov-2021 | Merger/Acquisition | 00.000 | Laboratory Services (Healthcare) | 00000 000 |
SenzaGen Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Toxhub | Consulting Services (B2B) | Rome, Italy | 2020 |
| VitroScreen | Laboratory Services (Healthcare) | Milan, Italy | 0000 |